Previous 10 | Next 10 |
2024-02-15 10:18:57 ET Summary MacroGenics, Inc. has a pipeline of promising drugs including Vobramitamab Duocarmazine, Lorigerlimab, Tebotelimab, MGD024, and IMGC936. The company has a strong financial position as of their latest report. MacroGenics faces both strengths and r...
2024-02-14 11:43:00 ET More on BioNTech, Moderna, etc. Pfizer Stock: It's Time To Buy The Dip Pfizer Is A Great Investment Over The Next Decade; Buy Pfizer: The 6.3% Yield Is A Appealing Federal judge dismisses PhRMA challenge to Medicare price negotiations ...
2024-02-14 08:15:00 ET Summary Markets continued to go higher in early 2024 with the Dow adding 0.4% and the S&P remaining flat in January. Interest rates were kept steady again in a range of 5.25% to 5.5% with the market now projecting fewer hikes this year as the economy rem...
2024-02-14 07:00:10 ET Brian Abrahams from RBC Capital issued a price target of $76.00 for GILD on 2024-02-14 06:54:00. The adjusted price target was set to $76.00. At the time of the announcement, GILD was trading at $73.53. The overall price target consensus is at $79....
2024-02-13 12:00:57 ET Summary Despite higher-than-expected inflation, stock markets remained largely unaffected, with the Dow Jones, Nasdaq, and S&P 500 Indices ignoring the news. Inflation for all items increased by 3.4%, with the shelter index accounting for two-thirds of t...
2024-02-13 09:04:41 ET Summary Gilead Sciences' acquisition of CymaBay Therapeutics introduces seladelpar into its portfolio, expanding its presence in liver diseases. Seladelpar shows clinical promise for PBC, with significant improvements in key liver health markers and pruritus...
NORTHAMPTON, MA / ACCESSWIRE / February 13, 2024 / Long-time liver specialist Carrie Frenette says she won't ever forget the people she treated for hepatitis C (HCV) before 2013 - the year that the Food and Drug Administration (FDA) approved a Gilead medicine. The medicine was the first curative...
2024-02-13 00:39:21 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2024-02-12 15:06:51 ET More on CymaBay, Gilead, etc. Gilead Sciences: Cheap For A Reason Gilead Sciences, Inc. (GILD) Q4 2023 Earnings Call Transcript Gilead Sciences, Inc. 2023 Q4 - Results - Earnings Call Presentation Gilead to acquire CymaBay for $32.50/sh...
2024-02-12 09:33:50 ET CymaBay Therapeutics Inc (NASDAQ: CBAY) opened more than 25% up this morning after Gilead Sciences Inc (NASDAQ: GILD) said it will buy the biopharmaceutical company for $4.3 billion. Details of Gilead-CymaBay agreement The said deal values CymaBay at $32.5...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...